Contribute to the early detection and prevention of infectious disease transmission
Leverage our proprietary Antisense molecular RNA diagnostic platform across multiple diseases
Create highly accurate, quick, affordable, easy to administer and minimally invasive disease diagnostic testing kits
The company’s Antisense molecular diagnostic platform is being developed for use at Point of Care (POC) to test on-site for a wide range of viral and other diseases.
The Company’s first product is an Antisense molecular Point of Care (POC) diagnostic test kit that accurately, quickly and affordably detects Covid-19 in less than 5 minutes.
Deployed at the point of entry of high traffic venues such as airports, shopping malls, office buildings, sporting venues, manufacturing plants, hospitals, pharmacies, nursing and long-term care homes the Antisense POC molecular diagnostic test kit will contribute to safe reopening of the economy.
RNA Disease Diagnostics, Inc. (RNADD) announced today the appointment of Richard G. Ganz to its Board of Directors. Mr. Ganz brings more than forty years of executive experience to RNADD, having worked with businesses ranging from venture-backed startups to major international healthcare companies.Read More
RNA Disease Diagnostics, Inc. (RNADD) announced today that the U.S. Food and Drug Administration (FDA) has registered the laboratory of Dipanjan Pan, MSc, PhD at the University of Maryland School of Medicine (UMSOM), as an approved laboratory development site for RNADD's Antisense COVID-19 molecular diagnostic test.Read More